Stockscreener 앱 받기
7.25
5.69%
0.39
시장 영업 전:
7.25
전일 마감가:
$6.86
열려 있는:
$6.97
하루 거래량:
28,314
Relative Volume:
0.14
시가총액:
$42.48M
수익:
$100.44M
순이익/손실:
$-133.16M
주가수익비율:
-0.2814
EPS:
-25.76
순현금흐름:
$-94.85M
1주 성능:
+5.07%
1개월 성능:
-15.60%
6개월 성능:
-25.41%
1년 성능:
-53.97%
1일 변동 폭
$6.6701
$7.25
1주일 범위
$5.94
$7.25
52주 변동 폭
$5.40
$20.81
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
ATRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.25 | 42.48M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.77 | 129.62B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
666.87 | 72.91B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
604.96 | 36.76B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.76 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.19 | 27.86B | 3.32B | -860.46M | -1.04B | -8.32 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
(ATRA) Investment Report - Stock Traders Daily
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World
Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks
Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - TipRanks
Atara Biotherapeutics Reports 2024 Financial Results - TipRanks
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz
Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St
Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock By Investing.com - Investing.com Australia
Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock By Investing.com - Investing.com South Africa
Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock - Investing.com Australia
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is i - GuruFocus.com
Atara biotherapeutics EVP sells $7,409 in common stock - Investing.com India
Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock - Investing.com India
Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily
Atara Biotherapeutics Inc To Cut 50% Of Workforce -March 03, 2025 at 05:26 pm EST - Marketscreener.com
Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet - MSN
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
(ATRA) Investment Analysis - Stock Traders Daily
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - Finansavisen
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-02-10 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Markets Insider
2025-02-09 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - Markets Insider
Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $17.75 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - Markets Insider
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.61%
자본화:
|
볼륨(24시간):